Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Empagliflozin

Omeed Sizar  1 , Vivek Podder  2 , Raja Talati  3
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Empagliflozin

Omeed Sizar et al.
Free Books & Documents

Excerpt

Empagliflozin is a medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medication for diabetes. This activity describes the indications, action, and contraindications for empagliflozin as a valuable agent in treating type 2 diabetes mellitus. This activity will highlight the mechanism of action, dosing, monitoring pertinent for members of the interprofessional team in the management of patients with type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Omeed Sizar declares no relevant financial relationships with ineligible companies.

Disclosure: Vivek Podder declares no relevant financial relationships with ineligible companies.

Disclosure: Raja Talati declares no relevant financial relationships with ineligible companies.

References

    1. Home P. Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia. 2019 Mar;62(3):357-369. - PubMed
    1. Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019 Mar 12;139(11):1384-1395. - PMC - PubMed
    1. Schwaiger E, Burghart L, Signorini L, Ristl R, Kopecky C, Tura A, Pacini G, Wrba T, Antlanger M, Schmaldienst S, Werzowa J, Säemann MD, Hecking M. Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant. 2019 Mar;19(3):907-919. - PMC - PubMed
    1. Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC. Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus. Clin Ther. 2016 Oct;38(10):2248-2264.e5. - PubMed
    1. Smyth B, Perkovic V. New hypoglycemic agents and the kidney: what do the major trials tell us? F1000Res. 2018;7 - PMC - PubMed

Publication types

LinkOut - more resources